Literature DB >> 34104221

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Anat Achiron1, Mathilda Mandel2, Sapir Dreyer-Alster2, Gil Harari2, David Magalashvili2, Polina Sonis2, Mark Dolev2, Shay Menascu2, Shlomo Flechter2, Rina Falb2, Michael Gurevich2.   

Abstract

Entities:  

Keywords:  COVID-19; cladrivine; finfolimod; mRNA vaccine; multiple sclerosis; ocrelizumab

Year:  2021        PMID： 34104221      PMCID： PMC8165862          DOI： 10.1177/17562864211020082

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


× No keyword cloud information.
  1 in total

1.  Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Authors:  Anat Achiron; Mathilda Mandel; Sapir Dreyer-Alster; Gil Harari; David Magalashvili; Polina Sonis; Mark Dolev; Shay Menascu; Shlomo Flechter; Rina Falb; Michael Gurevich
Journal:  Ther Adv Neurol Disord       Date:  2021-04-22       Impact factor: 6.570
  1 in total
  4 in total

Review 1.  SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.

Authors:  Ana Muñoz-Jurado; Begoña M Escribano; Eduardo Agüera; Javier Caballero-Villarraso; Alberto Galván; Isaac Túnez
Journal:  J Neurol       Date:  2022-07-05       Impact factor: 6.682

Review 2.  Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach.

Authors:  Paolo Immovilli; Nicola Morelli; Chiara Terracciano; Eugenia Rota; Elena Marchesi; Stefano Vollaro; Paola De Mitri; Domenica Zaino; Veronica Bazzurri; Donata Guidetti
Journal:  Neurol Int       Date:  2022-04-15

3.  Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.

Authors:  Steve Simpson-Yap; Ashkan Pirmani; Tomas Kalincik; Edward De Brouwer; Lotte Geys; Tina Parciak; Anne Helme; Nick Rijke; Jan A Hillert; Yves Moreau; Gilles Edan; Sifat Sharmin; Tim Spelman; Robert McBurney; Hollie Schmidt; Arnfin B Bergmann; Stefan Braune; Alexander Stahmann; Rod M Middleton; Amber Salter; Bruce Bebo; Anneke Van der Walt; Helmut Butzkueven; Serkan Ozakbas; Cavit Boz; Rana Karabudak; Raed Alroughani; Juan I Rojas; Ingrid A van der Mei; Guilherme Sciascia do Olival; Melinda Magyari; Ricardo N Alonso; Richard S Nicholas; Anibal S Chertcoff; Ana Zabalza de Torres; Georgina Arrambide; Nupur Nag; Annabel Descamps; Lars Costers; Ruth Dobson; Aleisha Miller; Paulo Rodrigues; Vesna Prčkovska; Giancarlo Comi; Liesbet M Peeters
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-08-29

4.  B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.

Authors:  Marco Iannetta; Doriana Landi; Gaia Cola; Laura Campogiani; Vincenzo Malagnino; Elisabetta Teti; Luigi Coppola; Andrea Di Lorenzo; Daniela Fraboni; Francesco Buccisano; Sandro Grelli; Marcello Mozzani; Maria Antonella Zingaropoli; Maria Rosa Ciardi; Roberto Nisini; Sergio Bernardini; Massimo Andreoni; Girolama Alessandra Marfia; Loredana Sarmati
Journal:  Front Immunol       Date:  2022-01-17       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.